Device Trial Radar · NCT06146231
Motiva Flora® Aesthetic Breast Recon® Clinical Study
Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Aug 18, 2023
Primary completion
Apr 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Establishment LabsPublic (ESTA)
- Sponsor type
- Industry
- Collaborators
- NAMSA
- First posted
- Nov 24, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study will be based on a hybrid breast reconstruction approach with initial skin expansion using the Motiva Flora® Tissue Expander followed by a serial fat grafting session and a final step that includes the placement of a permanent breast implant Ergonomix2®.
Conditions
- Mammaplasty
- Breast Cancer
- Poland Syndrome
Interventions
Motiva Flora® Tissue ExpanderDevice
This hybrid breast reconstruction involves a stage in which the tissue expander (Motiva Flora®) is used as intended for a conventional expansion. After achieving the desired volume, it is deflated in a controlled way to proceed with the execution of serial fat grafting procedures (reverse expansion). This also means the expander is implanted longer than indicated on its current Directions For Use. Once the reverse expansion is complete, the expander is replaced with a long-term breast implant. Motiva Implants Ergonomix2® Sterile Silicone Breast Implants will be used as per Standard of Care under the CE marked indication. To obtain the safest, most natural, and aesthetic outcomes, Ergonomix2® breast implants have been selected as the standard silicone breast implants for this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total adverse envent rateTime frame: 46 months
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
Hospital Universitario San Ignacio
Bogotá, Colombia · Not yet recruiting
Hospital UNIBE
San José, Costa Rica · Not yet recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.